Thrombolytic Science, LLC (TSI) is a privately-held vascular health and biotechnology company leading development of a next-generation, life-saving therapy to transform traditional medical ...

Practice Point Published: 31 July 2007 Thrombolytic therapy for ischemic stroke—suitable for children? Heather J Fullerton Nature Clinical Practice Neurology 3, 494–495 (2007) Cite this article ...

This article reviews the evidence supporting the use of thrombolytic therapy in persons older than 75 years of age with acute MI and concludes that the risk of major adverse events is acceptably low.

ABU DHABI, UAE — Thrombolytic treatment with recombinant human pro-urokinase was non-inferior to alteplase in achieving an excellent functional outcome in acute ischemic stroke but showed a ...

US Patents Complement Existing Patent Protection in the US, Europe, Japan, and China CAMBRIDGE, MA, January 05, 2022 / B3C newswire / -- Thrombolytic Science, LLC (TSI) has been granted a second ...

Thrombolytic therapy NEW YORK, August 7 (Praxis Press) Thrombolytic therapy for acute myocardial infarction is equally effective when delivered as a bolus injection and as a 60 to 90-minute infusion; ...

Biogen has licensed a new drug from Japanese biotech TMS that it hopes could provide a big advance on an old treatment approach – using clot-busting thrombolytic drugs to treat ischaemic stroke ...

PATIENTS AND METHODS: The study design was a phase III, open-label, single-arm multicenter trial. Subjects with occluded, nondialysis CVCs were enrolled. All subjects received a 2-mg dose of TPA ...

CAMBRIDGE, Mass., Oct. 2, 2012/ PRNewswire/-- Thrombolytic Science International today announced the initiation of a Phase 1 study of TS01, a new-generation clot-dissolving therapy intended for ...

Uniquely, the thrombolytic activity of BB-031 is designed to be quickly neutralized in the event of bleeding using a complementary agent, BB-025, which Basking is developing in tandem.

1 Recommendations This guidance provides recommendations on the selection of thrombolytic drugs in patients with acute myocardial infarction (AMI). Recommendations are made in relation to the use of ...